Rare Genetic Diseases: Faster Diagnosis for Children
- While the term "rare" suggests infrequency, rare genetic diseases collectively affect a meaningful portion of the population.
- Now, a team has developed a diagnostic test using proteomics to accelerate answers for families.
- The research centers on monogenic disorders,rare genetic diseases stemming from a single gene alteration or mutation.
A new proteomics approach promises far faster diagnosis of rare genetic diseases for children, possibly ending years of uncertainty. This cutting-edge test prioritizes genetic variants, aiming to shorten the “diagnostic odyssey” for countless families struggling to find answers.The research focuses specifically on monogenic disorders, like cystic fibrosis, which spring from single gene mutations. This innovative diagnostic tool, born from proteomics, could substantially impact the lives of the estimated 2 million Australians affected by these challenging conditions. News Directory 3 reports on the development, offering a glimpse into the future of medical diagnostics. What advances will this herald? Discover what’s next in this crucial area of medical breakthroughs.
Proteomics Approach Cuts Diagnosis Journey for Rare Genetic Diseases
Updated May 26, 2025
While the term ”rare” suggests infrequency, rare genetic diseases collectively affect a meaningful portion of the population. In Australia alone, about 2 million people, or 8% of the population, live with a rare genetic disease. Despite the numbers, families frequently enough face lengthy and complex paths to diagnosis.
Now, a team has developed a diagnostic test using proteomics to accelerate answers for families. The genomics revolution has already helped about 50% of families get a diagnosis within months. However, many endure a “diagnostic odyssey” involving years of tests, sometimes without a conclusive result.
The research centers on monogenic disorders,rare genetic diseases stemming from a single gene alteration or mutation. These include conditions such as cystic fibrosis and spinal muscular atrophy.
Daniella H. Hock, a lead researcher on the project, said the new test offers hope for faster diagnoses. “We’ve developed a diagnostic test that we hope will give families answers sooner,” Hock said.
What’s next
The team plans to further refine and implement the test, with the goal of making it widely accessible to families affected by rare genetic diseases, substantially reducing the time and uncertainty associated with diagnosis.